Gujarat Kidney and Superspeciality Hospital IPO GMP Today: Check Subscription Status and Key Details

Gujarat Kidney and Superspeciality Hospital IPO GMP has been the talk of the market since its opening on December 22, 2025. The healthcare company from Gujarat has opened its doors for public subscription with a fresh issue worth 250.80 crore rupees.

Retail investors are showing strong interest in this mainboard IPO which will close on December 24, 2025. The Gujarat kidney & super speciality IPO review shows mixed sentiments from market experts with some praising the growth story while others remain cautious about the premium valuation.

The company operates seven multispeciality hospitals with 490 beds across central Gujarat and specializes in nephrology, urology and renal transplantation services.

Also Read: ITR Filing Last Date 2025: Complete Registration Guide and Key Deadlines You Cannot Miss

Key Takeaways

• Gujarat Kidney and Superspeciality Hospital IPO opened on December 22, 2025 with price band of 108 to 114 rupees per share
• The IPO is fully subscribed on day 1 with retail investors leading at 5x subscription
• Gujarat kidney and superspeciality hospital ipo gmp today stands at 7 rupees indicating expected listing price around 121 rupees
• Fresh issue of 2.20 crore shares worth 250.80 crore rupees without any offer for sale component
• Minimum lot size is 128 shares requiring 14592 rupees investment at upper price band
• Anchor investors raised over 100 crore rupees on December 19, 2025
• Tentative listing date is December 30, 2025 on BSE and NSE

About Gujarat Kidney and Super Speciality Hospital

Gujarat Kidney and Super Speciality Limited is a regional healthcare provider operating in central Gujarat. The company runs seven multispeciality hospitals with total bed capacity of 490 beds.

Their core strength lies in nephrology, urology and renal transplantation services but they also offer treatment in cardiology, neurology, oncology, gastroenterology, orthopaedics and other medical specialities.

The company follows an asset light business model where they lease properties instead of owning them and focus on acquiring existing hospitals for expansion.

IPO Details and Price Band

The Gujarat kidney & super speciality gmp has caught investor attention. The price band is fixed between 108 to 114 rupees per equity share.

The lot size is 128 shares which means retail investors need to invest minimum 14592 rupees at the upper price band. The entire issue is a fresh issue of 2.20 crore shares without any offer for sale from existing shareholders.

This means promoters are not exiting and showing confidence in the company’s growth prospects.

Subscription Status Day 1

The subscription status on day 1 shows strong retail demand. Retail individual investors portion was subscribed 5.07 times which is the highest among all categories. Non institutional investors subscribed 1.98 times while qualified institutional buyers portion was subscribed only 0.34 times.

The overall subscription stands at 1.54 times on the first day itself. This retail enthusiasm suggests that small investors are betting on the regional healthcare story.

Gujarat Kidney and Superspeciality Hospital IPO GMP

Grey market premium is an unofficial indicator of listing gains. The Gujarat kidney and superspeciality hospital ipo gmp today is around 7 rupees over the upper price band of 114 rupees. This means the expected listing price could be around 121 rupees which translates to approximately 6 percent premium.

Earlier in the week the GMP was touching 10 rupees but has cooled down slightly. The current GMP suggests a decent but not spectacular listing day performance.

Use of IPO Proceeds

The company plans to use the money raised from this IPO for multiple purposes. Major chunk will go towards acquiring Parekhs Hospital in Ahmedabad and making partial payment for already acquired Ashwini Medical Centre.

They are also planning to set up a new hospital exclusively for women healthcare in Vadodara. The company will purchase robotics equipment for their Vadodara hospital and use some funds for debt repayment. Rest of the money will be used for general corporate purposes and unidentified future acquisitions.

Financial Performance and Valuation

The company has shown impressive growth numbers. Revenue jumped 637 percent and profit after tax surged 454 percent from FY24 to FY25. However these numbers should be seen in context as the consolidated business operations only started in 2024.

The pre IPO price to earnings ratio stands at around 61 times which is higher than sector peers like Yatharth Hospital and GPT Healthcare. Market analysts from SBI Securities have given a neutral rating citing limited near term valuation comfort but potential for medium to long term growth.

Expert Opinion and Market Sentiment

Market experts are divided on this IPO. The positive factors include strong revenue growth, asset light model, no promoter exit through offer for sale, and focus on high margin renal sciences segment.

The company also secured good anchor investor support with names like Venus Investments and Nexus Global Opportunities Fund participating. On the flip side concerns include premium valuation, limited operating history, regional concentration risk in Gujarat, execution challenges in planned acquisitions and expansions, and regulatory approval risks for new hospital setups.

Should You Subscribe

The decision to subscribe depends on your risk appetite and investment horizon. Short term listing gain seekers might find the current GMP of 7 rupees offering limited upside. Long term investors who believe in the healthcare sector growth story and the company’s expansion plans might consider applying.

Retail investors have shown strong confidence but institutional participation remains weak which is a mixed signal. The company operates in a growing sector with increasing healthcare needs in tier 2 and tier 3 cities of Gujarat.

Important Dates

The IPO subscription opened on December 22, 2025 and will close on December 24, 2025. Basis of allotment will be finalized on December 26, 2025. Refunds will be initiated and shares will be credited to demat accounts by December 29, 2025.

The tentative listing date on both BSE and NSE is December 30, 2025. Nirbhay Capital Services Private Limited is the book running lead manager while MUFG Intime India is the registrar for this issue.

Tags: gujarat kidney ipo, ipo gmp today, healthcare ipo 2025, mainboard ipo subscription, gujarat hospital ipo, nephrology hospital ipo, vadodara healthcare company

About Author